Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help...
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The...
Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on developing innovative therapies...
HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Cleared AI "SOMNUM"
Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency FDA-cleared AI solution shortens clinical trial timelines while ensuring data...
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing
1st production of pharmaceutical grade egg and milk challenge meals Product portfolio of challenge meals now includes peanut, milk and egg Innovation pipeline includes development of 'Top 9' allergen products as well as a products suitable from 6...
QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines
SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively...
AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND)...
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial...